We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

160 hedge funds and large institutions have $1.82B invested in Portola Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 64 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 13

94% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 33

92% more call options, than puts

Call options by funds: $1.62M | Put options by funds: $848K

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

44% more capital invested

Capital invested by funds: $1.26B → $1.82B (+$556M)

20% more funds holding

Funds holding: 133160 (+27)

Holders
160
Holders Change
+27
Holders Change %
+20.3%
% of All Funds
4.26%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
41
Increased
64
Reduced
33
Closed
13
Calls
$1.62M
Puts
$848K
Net Calls
+$776K
Net Calls Change
+$386K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$235M +$14.5M +422,100 +7%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$231M +$23.2M +674,553 +12%
Temasek Holdings
3
Temasek Holdings
Singapore
$221M
Vanguard Group
4
Vanguard Group
Pennsylvania
$92.4M +$10.7M +312,804 +15%
BFA
5
BlackRock Fund Advisors
California
$68.4M +$4.33M +125,966 +8%
Franklin Resources
6
Franklin Resources
California
$56.9M -$6.47M -188,226 -11%
EAM
7
Eagle Asset Management
Florida
$55.6M -$5.57M -162,113 -10%
State Street
8
State Street
Massachusetts
$47.7M +$387K +11,279 +0.9%
MAM
9
MPM Asset Management
Massachusetts
$46.3M
SAM
10
Sectoral Asset Management
Quebec, Canada
$44.1M +$1.45M +42,351 +4%
SCM
11
Scopia Capital Management
New York
$37.2M -$1.73M -50,326 -5%
Citadel Advisors
12
Citadel Advisors
Florida
$36.7M +$9.98M +290,598 +43%
JP Morgan Chase
13
JP Morgan Chase
New York
$36M -$4.36M -126,872 -12%
O
14
OrbiMed
New York
$32.3M
BIT
15
BlackRock Institutional Trust
California
$31.5M +$8.29M +241,385 +41%
Millennium Management
16
Millennium Management
New York
$26.9M +$11.8M +344,878 +95%
Jennison Associates
17
Jennison Associates
New York
$24.4M +$70.7K +2,058 +0.3%
DM
18
Deerfield Management
New York
$21.8M -$2.78M -81,013 -12%
CAM
19
Cormorant Asset Management
Massachusetts
$21.8M -$876K -25,500 -4%
PC
20
Polar Capital
United Kingdom
$21.5M -$3.17M -92,282 -14%
Northern Trust
21
Northern Trust
Illinois
$19.3M +$552K +16,060 +3%
FAM
22
Fred Alger Management
New York
$18.3M -$8.44M -245,623 -34%
EA
23
Emerald Advisers
Pennsylvania
$15.7M +$1.38M +40,151 +10%
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$15.5M -$718K -20,896 -5%
EAM
25
Eventide Asset Management
Massachusetts
$15.4M +$1.13M +32,900 +9%

PTLA Hedge Fund Activity: Q1 2015 in Review

160 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2015, worth a combined $1.82B — up 44% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PTLA positions and 13 closed out — a net gain of 28 holders — while 64 added to existing stakes and 33 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $23.2M. The largest seller was Abingworth, cutting an estimated $20M.

  • 160 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2015, up from 133 in Q4 2014.
  • Funds reported $1.82B of Portola Pharmaceuticals, Inc. stock for Q1 2015, up 44% quarter-over-quarter.
  • 41 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2015 and 13 closed out, a net change of +28 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q1 2015 was Wellington Management Group, an estimated $23.2M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q1 2015 was Abingworth, an estimated $20M sold.

Based on aggregated 13F filings for Q1 2015.